The Baruch S. Blumberg Institute

What The Baruch S. Blumberg Institute does

The Baruch S. Blumberg Institute is a nonprofit translational research organization founded in 2003 and headquartered in Doylestown, Pennsylvania, where it operates from the Pennsylvania Biotechnology Center (PABC) campus. Its scientific mandate is the pathobiology and curative therapy of hepatitis B virus (HBV), with secondary programs in liver cancer diagnostics, yellow fever antiviral discovery, and broader antiviral and precision-medicine research. Core platforms include HBV cccDNA biosynthesis and targeting, capsid assembly modulators (CAMs), a first-in-class orally bioavailable yellow fever NS4B inhibitor program, the HBV-RADARS RNA-sensing/ADAR-editing gene therapy system, urine-based biomarkers for early liver disease detection, and PROTAC-modified dihydroquinolizinones for hepatitis A and B.

The Institute is also a life-sciences cluster operator: it manages the PABC in Doylestown (~100 tenant companies) and the B+labs incubator at Philadelphia's Cira Centre (50,000 sq ft, in partnership with Brandywine Realty Trust), and was selected by New York State to build and manage the BioGenesis cell-and-gene-therapy center on Long Island with $50M in state funding. Revenue is derived from federal grants and contracts (NIH, NIAID, NCI, CDC, FDA, DoD), state economic-development grants, philanthropic donations, technology licensing, and incubator management services. It shares leadership, faculty, and board overlap with its parent, the Hepatitis B Foundation, and is led by CEO Louis P. Kassa III and President Ju-Tao Guo (appointed October 2025). Faculty include distinguished professors with prior industry track records of bringing multiple approved drugs to market (Eliquis, sofosbuvir, daclatasvir, fostemsavir).

Name

The Baruch S. Blumberg Institute

Legal name

The Baruch S. Blumberg Institute

Website

https://blumberginstitute.org

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

The Baruch S. Blumberg Institute is a Doylestown, PA-based nonprofit translational research organization founded in 2003 that discovers therapeutics and diagnostics for hepatitis B, liver cancer, and viral diseases, while managing the Pennsylvania Biotechnology Center incubator and adjacent life-sciences cluster operations.

Ownership category

akta.pro rank

Product category

Translational Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

Keywords

• Translational research
• Hepatitis B research
• Antiviral drug discovery
• Biotech incubator services
• Liver cancer diagnostics

Headquarters

HQ city

Doylestown

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Federal Research Grants and Contracts: Primary revenue from NIH, NIAID, NCI, CDC, FDA, and Department of Defense research grants and contracts. Includes a major $32.3M contract for yellow fever drug development and multiple SBIR grants.
2. Donations and Philanthropy: Revenue from individual donors, foundations (e.g., Raymond F. Schinazi & Family Foundation), and corporate gifts. Also receives equity positions in spinout companies.
3. Incubator Management Services: Revenue from managing Pennsylvania Biotechnology Center and B+labs incubator facilities, including potential management fees for new ventures like the BioGenesis center
4. Technology Licensing: Licensing of developed technologies and intellectual property to biotech companies

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

The Baruch S. Blumberg Institute is a nonprofit translational research organization that discovers and develops therapies and diagnostics for hepatitis B virus infection, hepatitis D, and liver cancer, and operates life-sciences incubator campuses (Pennsylvania Biotechnology Center, B+labs at Cira Centre, and BioGenesis Center) that house and support early-stage biotechnology companies. It also delivers workforce training, public-health programming, and scientific conferences to advance HBV and liver-disease research and education.

Product overview

The Baruch S. Blumberg Institute is a nonprofit translational research organization (not a commercial product company) that conducts research programs in virology and viral pathogenesis, antiviral drug discovery and development, biopharmaceutics, precision medicine, public health research, and Pennsylvania Cancer and Regenerative Medicine. The Institute also manages the Pennsylvania Biotechnology Center (PABC) as a life sciences incubator and offers training and education programs including summer internships, high school programs, and seminars. It does not offer commercial products or software services.

Differentiator

Problem solved

Functional benefit

Products and services

• Pennsylvania Biotechnology Center (PABC) Incubator Services Operated by the Baruch S. Blumberg Institute, PABC is a life-sciences incubator in Doylestown, PA that provides wet-lab and office space, shared core facilities (including vivarium and instrumentation), and a collaborative research campus environment to more than 50 early- and mid-stage biotechnology companies, with the full Doylestown campus supporting more than 400 scientists, staff, and residents.
• B+labs at Cira Centre Incubator Services A second life-sciences incubator operated by the Baruch S. Blumberg Institute, located in the Cira Centre in Philadelphia, PA, providing shared lab and office space, shared equipment, and programming for resident biotech startups in an urban innovation-district setting.
• BioGenesis Center Incubator Services A third life-sciences incubator operated by the Baruch S. Blumberg Institute, located on Long Island, NY, offering lab, office, and shared research space to early-stage biotechnology companies.
• Translational Research and Drug-Discovery Collaboration Services Research services in virology, biopharmaceutics, precision medicine, cancer research, and public health, including discovery and development of HBV capsid assembly modulators, NS4B inhibitors, PROTAC dihydroquinazolinone degraders, HBV-RADARS diagnostic biomarker assays, urine-based hepatocellular carcinoma biomarkers, and HBV cccDNA-based assays, conducted for and with federal, academic, and industry partners.

Quantifiable outcome

• PABC companies created $7.3 billion in economic impact and 1,100+ jobs during 2016-2021
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• New York State (BioGenesis)coreStrategic or Co-development Partner · 22 October 2024Selected by New York State officials to build and manage BioGenesis, a cell and gene therapy center and biotech incubator on Long Island. Supported by $50 million investment from ESD's Long Island Investment Fund. This expands the Institute's national presence.
• Brandywine Realty TrustcoreStrategic or Co-development Partner · 20 December 2023Partnership to support advancement of life sciences companies in Greater Philadelphia. Brandywine provides real estate platform and facilities while the Institute contributes scientific ecosystem and expertise. Includes B+labs at Cira Centre incubator and Hatch BioFund collaboration.
• Hatch BioFund Management LLCcoreStrategic or Co-development Partner · 20 December 2023Early-stage life sciences venture capital firm formed with participation from the Institute and PABC. Provides investment capital and industry expertise to promising life science companies in the Greater Philadelphia region.
• The Wistar InstitutecoreStrategic or Co-development Partner · 9 May 2023Strategic collaboration between Wistar Institute, PABC, and Blumberg Institute to accelerate bench-to-bedside translation. Helps attract talent, new capital, and resources to the regional biomedical research pipeline.
• Pennsylvania Biotechnology Center (PABC)coreStrategic or Co-development PartnerThe Institute manages the PABC, a nonprofit life sciences incubator-accelerator with nearly 100 member companies. The Institute provides research oversight and leverages the incubator ecosystem for technology commercialization.
• Hepatitis B FoundationcoreStrategic or Co-development PartnerFounded in 2003 by the Hepatitis B Foundation to advance its research mission. Organizations share leadership, facilities, and mission alignment for hepatitis B cure research.
• Arbutus BiopharmaminorStrategic or Co-development PartnerCollaboration on hepatitis B drug discovery programs, including Capsid Assembly Modulators (CAMs) and other antiviral compounds. Located in Warminster, PA.
• Fox Chase Cancer CenterminorStrategic or Co-development PartnerAcademic partnership providing postdoctoral training opportunities and collaborative research in virology and cancer biology.
• Drexel University College of MedicineminorStrategic or Co-development PartnerAcademic partnership where Dr. Guo was faculty before joining the Institute. Ongoing collaboration in microbiology and immunology research.

Scale indicators14 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• LabCentral: Nonprofit biotech incubator operating shared laboratory facilities for early-stage life-sciences startups, analogous to PABC and B+labs which Blumberg manages. Directly comparable business model of providing lab infrastructure to portfolio biotechs.
• The Wistar Institute: Independent nonprofit biomedical research institute also based in Pennsylvania with a similar focus on virology, immunology, and translational research. Wistar has an existing strategic collaboration with Blumberg/PABC, making it the closest peer in mission, geography, and operating model.
• MBC BioLabs: Nonprofit biotech incubator offering fully equipped lab space and shared services to early-stage companies — direct functional analog to PABC and the planned BioGenesis center. Highly comparable operating model and tenant base.
• Fox Chase Cancer Center: Philadelphia-area biomedical research and cancer center with overlapping virology and postdoctoral training relationships. Comparable in disease focus, location, and academic partnership structure.

Broad incumbents

• Research Triangle Institute (RTI International): Independent nonprofit research institute delivering scientific and translational R&D services across health, energy, and technology. Comparable as a large-scale nonprofit research organization with significant federal contract revenue.
• Allen Institute: Independent nonprofit medical research organization running large-scale translational and discovery science programs. Comparable as a research-driven nonprofit that combines scientific output with commercialization of biological tools and findings.
• Salk Institute for Biological Studies: Independent nonprofit research institute focused on fundamental biological research with translational programs in cancer, immunology, and disease biology. Comparable in operating model (nonprofit, faculty-driven, NIH-funded) and research scope.
• JLABS (Johnson & Johnson Innovation): Global network of life-sciences incubators operated by J&J Innovation, similar in function to PABC and B+labs but backed by a strategic rather than nonprofit sponsor. Comparable as an incubator-of-biotech-startups platform.
• Scripps Research: Large nonprofit translational research organization conducting fundamental biomedical and pharmaceutical research with multiple drug-discovery programs. Comparable in scale, nonprofit model, and emphasis on bench-to-bedside translation.
• Cold Spring Harbor Laboratory: Independent nonprofit research and educational institution delivering fundamental biomedical research with translational application. Comparable in nonprofit operating model, faculty-resident structure, and significant NIH funding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/BlumbergInstit1
• Facebookfacebook.com/BaruchSBlumberg
• LinkedInlinkedin.com/company/baruch-s-blumberg-institute
• Instagraminstagram.com/blumberginstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Baruch S. Blumberg Institute